NICE publishes final recommendation for Almirall`s ILUMETRI®
(WorldNews Spain)

United Kingdom April 17th 2019 Almirall, S.A. (ALM) announced today that the NICE (National Institute for Health and Care Excellence, in the UK) has published its final guidance approving ILUMETRI® (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for treating adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.1 Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of tildrakizumab and has recommended tildrakizumab as a cost effective treatment option for the NHS for the patients...